{
    "clinical_study": {
        "@rank": "107642", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (lower dose curcumin)", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of Breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80\u00b0C for biomarker analyses. Assessment of Dietary Intake will be assessed through food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications."
            }, 
            {
                "arm_group_label": "Arm II (higher dose curcumin)", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of Breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80\u00b0C for biomarker analyses. Assessment of Dietary Intake will be assessed through food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot clinical trial studies a nanoemulsion formulation of curcumin in\n      reducing inflammatory changes in breast tissue in obese women at high risk for breast\n      cancer. Curcumin may reduce inflammation in breast tissue and fat. This may affect the risk\n      of developing breast cancer."
        }, 
        "brief_title": "Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer", 
        "condition": [
            "Atypical Ductal Breast Hyperplasia", 
            "BRCA1 Gene Mutation", 
            "BRCA2 Gene Mutation", 
            "Ductal Breast Carcinoma in Situ", 
            "Lobular Breast Carcinoma in Situ"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma in Situ", 
                "Carcinoma, Intraductal, Noninfiltrating", 
                "Hyperplasia", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Lobular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      i.) To determine whether nanoemulsion curcumnin modulates pro-inflammatory biomarkers in\n      plasma and breast adipose tissue.\n\n      SECONDARY OBJECTIVES include:\n\n      ii.) To determine the adherence, tolerability and safety of two doses of nanoemulsion\n      curcumin (NEC) in women at high risk for developing breast cancer;\n\n      iii.) Evaluate possible correlations between physical factors such as body mass index (BMI),\n      dietary intake and pro-inflammatory effects in plasma and breast adipose tissue.\n\n      iv.) Explore additional biomarkers as surrogate endpoints to measure effects of NEC.\n\n      OUTLINE: Participants are randomized to 1 of 2 arms.\n\n      ARM I: Participants receive lower dose of nanoemulsion curcumin orally (PO) twice daily\n      (BID) for 3 months.\n\n      ARM II: Participants receive 100 mg of nanoemulsion curcumin PO BID for 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Increased risk for breast cancer based on family history, personal history\n\n          -  Normal mammogram, clinical breast examination in the past 12 months\n\n          -  >1 year from pregnancy, lactation or chemotherapy\n\n          -  Body mass index (BMI) between 30 - 40\n\n        EXCLUSION CRITERIA:\n\n          -  Concurrent malignancy or metastatic malignancy of any kind\n\n          -  Ongoing chemotherapy, radiation therapy, or other cancer-related treatment\n\n          -  History of a bleeding tendency or current use of Coumadin or other anticoagulants\n\n          -  Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or\n             renal disease, viral, bacterial, atypical or fungal infections of any organ system\n             and human immunodeficiency virus (HIV) infection\n\n          -  Pregnant or lactating women\n\n          -  Concurrent use of hormonal contraception or hormone replacement therapy\n\n          -  Concurrent use of immunosuppressant medications\n\n          -  Concurrent use of antacids, hydrogen (H2) antagonists, proton-pump inhibitors, or\n             medications known to inhibit or induce hepatic enzyme cytochrome P450 (CYP) 3A4\n\n          -  Barriers to fine needle aspiration sampling of breast adipose, including breast\n             implants, history of radiation to both breasts, bilateral mastectomies, and/or\n             insufficient breast adipose tissue for adequate fine needle aspiration (FNA) sampling\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, hypertension, or psychiatric illness/social situation that would limit\n             compliance with study requirements\n\n          -  Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids\n             within the 3 months prior to entry on the study or any other supplements that might\n             interact with NEC\n\n          -  Known sensitivity or allergy to turmeric spices or curry\n\n          -  Dietary intake of large amounts of curry, turmeric spices or black pepper on a\n             regular basis\n\n          -  Subjects on a standing regimen of full dose aspirin (>= 325 mg/day), non-steroidal\n             anti-inflammatory drug (NSAID)s or NSAID-containing products"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01975363", 
            "org_study_id": "OSU-13034", 
            "secondary_id": "NCI-2013-01199"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm I (lower dose curcumin)", 
                    "Arm II (higher dose curcumin)"
                ], 
                "description": "Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.", 
                "intervention_name": "curcumin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "C.I. 75300", 
                    "C.I. Natural Yellow 3", 
                    "CU", 
                    "Diferuloylmethane", 
                    "NEC"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (lower dose curcumin)", 
                    "Arm II (higher dose curcumin)"
                ], 
                "description": "Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80\u00b0C for biomarker analyses.", 
                "intervention_name": "Biomarker analysis", 
                "intervention_type": "Other", 
                "other_name": [
                    "Correlative studies", 
                    "Breast adipose tissue", 
                    "plasma samples"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm I (lower dose curcumin)", 
                    "Arm II (higher dose curcumin)"
                ], 
                "description": "Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.", 
                "intervention_name": "Assessment of Dietary Intake", 
                "intervention_type": "Other", 
                "other_name": "questionnaires"
            }, 
            {
                "arm_group_label": [
                    "Arm I (lower dose curcumin)", 
                    "Arm II (higher dose curcumin)"
                ], 
                "description": "All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.", 
                "intervention_name": "Daily Log", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Curcumin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Breast Cancer", 
        "lastchanged_date": "October 28, 2013", 
        "link": {
            "description": "Jamesline", 
            "url": "http://cancer.osu.edu"
        }, 
        "location": {
            "contact": {
                "email": "Lisa.yee@osumc.edu", 
                "last_name": "Lisa D. Yee", 
                "phone": "614-293-6654"
            }, 
            "facility": {
                "address": {
                    "city": "Columbus", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "43210"
                }, 
                "name": "Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center"
            }, 
            "investigator": {
                "last_name": "Lisa D. Yee, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial", 
        "overall_contact": {
            "email": "Jamesline@osumc.edu", 
            "last_name": "Ohio State University Comprehensive Cancer Center", 
            "phone": "1-800-293-5066"
        }, 
        "overall_contact_backup": {
            "email": "Lisa.Yee@osumc.edu", 
            "last_name": "Lisa Yee, MD", 
            "phone": "614-293-6654"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University Comprehensive Cancer Center", 
            "last_name": "Lisa Yee, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Confidence interval estimates will be obtained from the repeated analysis of variance and two-sample t tests.", 
            "measure": "Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin (NEC)in women at high risk for developing breast cancer.", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01975363"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ohio State University Comprehensive Cancer Center", 
            "investigator_full_name": "Lisa Yee", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Evaluate possible correlations between physical factors such as body mass (BMI), dietary intake and pro-inflammatory effects in plasma and breast adipose tissue.", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months"
        }, 
        "source": "Ohio State University Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ohio State University Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}